Annovis Bio

ANNOVIS BIO

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

London,,United,Kingdom,,March,1st,2025:,Poster,Of,Singer,Beyoncé

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ANVS

CSCO

DAVA

GROV

IBTA

LEVI

NEXN

SMTI

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Biotech

Earnings

Earnings Misses

Penny Stocks

Small Cap

General

AKRO

EDIT

VRTX

Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.

Editas Q2 Earnings &amp; Revenues Miss Estimates, Stock Down

Earnings Beats

ARQT

IMMP

Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) study.

Immutep Up as Combo Therapy Meets Carcinoma Study Goals

Annovis Bio Inc

Health Care

Press Releases

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis to Host Patients' Live Forum on February 27, 2025

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Management

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Avalo Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kronos Bio

Lantern Pharma

OS Therapies

Pluri

PMV Pharma

Quince Therapeutics

Rein Therapeutics

RenovoRx

Spero Therapeutics

Xilio Therapeutics

Canaccord Genuity

HC Wainwright & Co.

Maxim Group

EF Hutton

Rodman & Renshaw

Comments

Annovis Bio

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell